Research Article
IFNL4 ss469415590 Variant Is Associated with Treatment Response in Japanese HCV Genotype 1 Infected Individuals Treated with IFN-Including Regimens
Table 4
Comparison of SVR and non-SVR patients treated with peginterferon and ribavirin by univariate analysis (a) and multivariate analysis (b).
(a) Univariate analysis |
| | SVR, | Non-SVR, | values (SVR versus non-SVR groups) |
| Gender, male/female | 39/33 | 34/40 | 0.40 | Age, years | 54.4 ± 12.7 | 57.0 ± 9.3 | 0.15 | Previous treatment: naïve/relapse/null | 59/12/1 | 43/14/17 | 0.00020 | AST, IU/L | 54.1 ± 54.3 | 61.8 ± 42.5 | 0.34 | ALT, IU/L | 69.0 ± 71.5 | 73.0 ± 58.2 | 0.71 | γ-GTP, IU/L | 42.7 ± 41.3 | 70.0 ± 85.7 | 0.0158 | Hemoglobin, g/dL | 13.9 ± 1.1 | 14.1 ± 1.3 | 0.31 | Platelets, ×104/mm3 | 17.8 ± 5.4 | 15.7 ± 5.9 | 0.0265 | Treatment response | | | | RVR, | 15 | 0 | 0.000107 | EVR, | 53 | 12 | <0.0001 | IFNL4, ss469415590, major/minor/ND | 60/10/2 | 33/38/3 | <0.0001 |
|
|
Null: null response; AST: aspirate aminotransferase; ALT: alanine aminotransferase; γ-GTP: γ-glutamyltransferase; RVR: rapid virological response; EVR: early virological response; SVR: sustained virological response.
|
(b) Factors associated with SVR among patients treated with peginterferon plus ribavirin by multivariate analysis |
| Factor | Category | Odds ratio | 95% CI | values |
| IFNL4, ss469415590 | major/minor | 2.56 | 1.005–6.557 | 0.0486 | EVR | +/− | 10.16 | 4.28–24.10 | <0.0001 |
|
|
EVR: early virological response.
|